Reproductive Endocrinology — MCQs

Q: Testicular feminization syndrome is characterized by all of the following except?

Presence of Barr body. **Explanation:** **Testicular Feminization Syndrome (now known as Complete Androgen Insensitivity Syndrome - CAIS)** is a condition where a genetic male (46, XY) has a total resistance to androgens due to a defect in the androgen receptor. **Why Option D is the Correct Answer:** The **Barr body** represents an inactivated X chromosome, typically found in individuals with more than one X chromosome (e.g., 46, XX females or 47, XXY males). Since CAIS patients have a **46, XY genotype**, they possess only one X chromosome, which remains active. Therefore, they are **Barr body negative**. **Analysis of Other Options:** * **A. Absent uterus:** In these patients, the testes are present (usually intra-abdominal) and secrete **Anti-Müllerian Hormone (AMH)**. AMH causes the regression of Müllerian structures, leading to the absence of the uterus, fallopian tubes, and upper third of the vagina. * **B. Primary amenorrhea:** Due to the absence of a uterus and ovaries, these patients typically present during puberty with a failure to start menstruation. * **C. Normal breast development:** Peripheral conversion of testosterone to estrogen (aromatization) occurs. Since there is no androgen action to oppose this estrogen, patients develop normal, often feminine, breast contours (though the nipples/areolae may be pale). **High-Yield Clinical Pearls for NEET-PG:** * **Karyotype:** 46, XY (Genetically male, Phenotypically female). * **Gonads:** Testes (Risk of gonadoblastoma; gonadectomy is recommended after puberty/attainment of height). * **Hair:** Characteristically **absent or scanty** axillary and pubic hair (due to androgen resistance). * **Vagina:** Blind-ending pouch (short vagina). * **Differential Diagnosis:** **Müllerian Agenesis (MRKH Syndrome)**. Distinguishing factor: MRKH has a 46, XX karyotype, normal pubic hair, and normal ovaries.

Q: A female presents with normal breast development but scanty pubic hair. What is the most likely diagnosis?

Testicular feminizing syndrome. **Explanation:** The clinical presentation of **normal breast development** paired with **scanty or absent pubic/axillary hair** is a classic hallmark of **Androgen Insensitivity Syndrome (AIS)**, historically known as **Testicular Feminizing Syndrome**. **1. Why the Correct Answer is Right:** In AIS, the individual has a **46, XY** karyotype and functioning testes that produce testosterone. However, due to a defect in androgen receptors, the body cannot respond to testosterone. * **Breast Development:** Occurs because the high levels of testosterone are peripherally converted to estrogen (aromatization). * **Scanty Pubic Hair:** Pubic and axillary hair growth is dependent on androgens. Since the receptors are non-functional, hair growth is minimal or absent. * **Anatomy:** MIF (Müllerian Inhibiting Factor) is produced, so there is no uterus or fallopian tubes (blind-ending vagina). **2. Why Incorrect Options are Wrong:** * **Turner’s Syndrome (45, XO):** Characterized by "streak gonads" and low estrogen. Patients typically present with **primary amenorrhea and absent breast development** (sexual infantilism). * **Müllerian Agenesis (MRKH Syndrome):** These patients are **46, XX** with normal ovaries. They have **normal breast development AND normal pubic hair** (since androgen receptors are functional), but lack a uterus and upper vagina. * **Gonadal Dysgenesis:** Similar to Turner’s, the lack of functional gonads leads to estrogen deficiency, resulting in a lack of secondary sexual characteristics (no breast development). **High-Yield Clinical Pearls for NEET-PG:** * **Karyotype:** AIS is 46, XY; MRKH is 46, XX. * **Gonads:** In AIS, testes are often found in the inguinal canal or abdomen (risk of gonadoblastoma; requires removal after puberty). * **Differential Diagnosis:** The presence or absence of pubic hair is the most important clinical differentiator between AIS (absent) and MRKH (present).

Q: Which of the following tests can differentiate Mullerian agenesis (MRKH syndrome) from complete androgen insensitivity syndrome (testicular feminization syndrome)?

Karyotyping. **Explanation:** Both **Mullerian Agenesis (MRKH Syndrome)** and **Complete Androgen Insensitivity Syndrome (CAIS)** present with primary amenorrhea, a blind vaginal pouch, and well-developed breasts. However, their underlying genetic and hormonal profiles are fundamentally different. **Why Karyotyping is the Correct Answer:** Karyotyping is the definitive diagnostic tool to differentiate these two conditions. * **MRKH Syndrome:** Patients are genetically female (**46, XX**). They have normal ovaries and female-range testosterone levels. * **CAIS:** Patients are genetically male (**46, XY**). They have undescended testes and male-range testosterone levels, but appear phenotypically female because their tissues are unresponsive to androgens. **Analysis of Incorrect Options:** * **A & B (3D Ultrasound/MRI):** While both imaging modalities are excellent for identifying the absence of a uterus and cervix, they cannot reliably distinguish between a 46,XX individual (MRKH) and a 46,XY individual (CAIS) based solely on pelvic anatomy, as both lack Mullerian structures. * **D (Serum Testosterone):** While testosterone levels are significantly higher in CAIS (male range) than in MRKH (female range), **Karyotyping** remains the gold standard for definitive diagnosis and is the preferred initial step in the workup of primary amenorrhea with absent internal organs. **High-Yield Clinical Pearls for NEET-PG:** 1. **Pubic/Axillary Hair:** This is the most important clinical differentiator. It is **normal** in MRKH but **absent or scanty** in CAIS (due to androgen resistance). 2. **Gonads:** In MRKH, ovaries are present (normal ovulation/hormones). In CAIS, testes are present (usually intra-abdominal or inguinal). 3. **Management:** In CAIS, the gonads must be removed (gonadectomy) after puberty to prevent malignancy (gonadoblastoma/dysgerminoma). In MRKH, the focus is on vaginal creation (dilatation or vaginoplasty).

Q: A 20-year-old young woman presents with a history of rapidly developing hirsutism and amenorrhea with a change in voice. Which of the following blood tests would be most appropriate to establish a diagnosis?

Testosterone. **Explanation:** The clinical presentation of **rapidly developing hirsutism**, **amenorrhea**, and **virilization** (deepening of voice) in a young woman is highly suggestive of an **androgen-secreting tumor** (ovarian or adrenal). 1. **Why Testosterone is the correct answer:** In cases of rapid-onset virilization, the primary goal is to rule out a testosterone-secreting ovarian tumor (e.g., Sertoli-Leydig cell tumor). Serum **Total Testosterone** levels >200 ng/dL are a strong biochemical marker for such neoplasms. While PCOS causes gradual hirsutism, a sudden onset with virilization points toward malignancy or a functional tumor, making testosterone the most critical initial diagnostic test. 2. **Why other options are incorrect:** * **17-hydroxyprogesterone:** This is the screening test for **Congenital Adrenal Hyperplasia (CAH)**. While CAH causes hirsutism, it is usually present from childhood/puberty and rarely presents with such a rapid, fulminant course in a 20-year-old. * **DHEA/DHEA-S:** DHEA-S is a marker for **adrenal** sources of androgens. While it should be measured if an adrenal tumor is suspected (levels >700 µg/dL), Testosterone is generally the more sensitive first-line marker for overall virilization. * **LH/FSH ratio:** This is used to support a diagnosis of **PCOS** (where the ratio is often >2:1). However, PCOS causes slow, progressive hirsutism and does not typically cause voice changes (virilization). **Clinical Pearls for NEET-PG:** * **Rapid onset + Virilization** = Think Androgen-secreting Tumor. * **Gradual onset + Obesity + Irregular periods** = Think PCOS. * **Testosterone >200 ng/dL:** Evaluate for Ovarian Tumor (e.g., Sertoli-Leydig). * **DHEA-S >700 µg/dL:** Evaluate for Adrenal Tumor. * **Deepening of voice and clitoromegaly** are signs of virilization, not just hirsutism, and always require urgent investigation to rule out malignancy.

Q: A young female presented with primary amenorrhea. Examination reveals normal breast development and absent axillary hairs. Pelvic examination shows a normally developed vagina with clitoromegaly. On ultrasound, gonads are visible in the inguinal region. What is the most likely diagnosis?

Partial androgen insensitivity syndrome. **Explanation:** The clinical presentation hinges on the spectrum of **Androgen Insensitivity Syndrome (AIS)**, an X-linked recessive condition where a 46,XY individual has a functional defect in androgen receptors. **Why Partial AIS (PAIS) is correct:** In PAIS, there is partial responsiveness to androgens. The presence of **clitoromegaly** (ambiguous genitalia) and **axillary hair** (though often sparse, its presence or the virilization of genitalia distinguishes it from the "Complete" form) are hallmark signs. The patient has normal breast development due to the peripheral conversion of testosterone to estrogen. The presence of **inguinal gonads** (testes) and a short/blind-ending vagina (due to Anti-Müllerian Hormone production by testes) confirms the diagnosis. **Why other options are incorrect:** * **Complete AIS (CAIS):** Presents with a purely female phenotype. There is **no clitoromegaly** and characteristically **absent or very scanty** axillary/pubic hair. * **MRKH Syndrome:** These are 46,XX individuals with normal ovaries. They would have **normal axillary/pubic hair** (normal adrenarche) and no clitoromegaly or inguinal testes. * **Gonadal Dysgenesis (e.g., Turner Syndrome):** Typically presents with **absent breast development** (due to ovarian failure/streak gonads) and elevated gonadotropins. **High-Yield Clinical Pearls for NEET-PG:** * **Karyotype:** Both CAIS and PAIS are **46,XY**. * **The "Hair" Rule:** CAIS = Hairless (absent axillary/pubic hair); MRKH = Hairy (normal hair). * **Management:** In AIS, gonads are removed after puberty (to allow natural height gain and breast development) to prevent **gonadoblastoma/dysgerminoma**, followed by estrogen replacement. * **Differential:** If a patient has primary amenorrhea, absent uterus, but **normal male-range testosterone**, think AIS. If testosterone is in the **female range**, think MRKH.

Q: Which of the following is the best diagnostic method for confirming ovulation?

Endometrial biopsy. **Explanation:** The correct answer is **Endometrial biopsy**. While several methods can suggest ovulation, an endometrial biopsy is traditionally considered the "gold standard" for confirming that ovulation has occurred and that the corpus luteum is producing adequate progesterone. **1. Why Endometrial Biopsy is Correct:** Ovulation is followed by the formation of the corpus luteum, which secretes **progesterone**. Progesterone induces specific **secretory changes** in the endometrium. Performing a biopsy during the mid-luteal phase (typically day 21-23 of a 28-day cycle) and finding secretory endometrium provides definitive histological proof that the ovary has been exposed to progesterone, thus confirming prior ovulation. **2. Why Other Options are Incorrect:** * **A. Ultrasound:** Serial transvaginal sonography (Folliculometry) is excellent for monitoring follicular growth and disappearance (suggesting rupture), but it is an indirect visualization and cannot confirm the functional hormonal status as accurately as histology. * **B. Laparoscopy:** While it can visualize a *corpus hemorrhagicum* or a stigma on the ovary, it is an invasive surgical procedure and not a routine diagnostic tool for confirming ovulation. * **D. Chromotubation:** This is a procedure performed during laparoscopy to check for **tubal patency** using methylene blue dye; it has no role in assessing ovulation. **NEET-PG High-Yield Pearls:** * **Most accurate single-day test:** Serum Progesterone levels >3 ng/ml (measured on Day 21) are the most common clinical method to confirm ovulation. * **Luteal Phase Defect (LPD):** Diagnosed if the endometrial dating lags by more than 2 days behind the actual menstrual day. * **Spinnbarkeit Effect:** Refers to the elasticity of cervical mucus under estrogen influence (pre-ovulatory); this disappears after ovulation due to progesterone.

Q: What is the effect of elevated androgens on hair follicles in Polycystic Ovary Syndrome (PCOS)?

Conversion of vellus hair to terminal hair.. In Polycystic Ovary Syndrome (PCOS), hyperandrogenism is a hallmark feature. The effect of androgens on hair follicles is site-specific and mediated primarily by the conversion of Testosterone to **Dihydrotestosterone (DHT)** via the enzyme **5α-reductase** within the hair follicle. ### **Explanation of the Correct Answer (B)** In androgen-sensitive areas (face, chest, lower abdomen), elevated levels of androgens act on **vellus hairs**—which are fine, short, and non-pigmented—and stimulate their transformation into **terminal hairs**, which are coarse, long, and darkly pigmented. This process is known as **hirsutism**. ### **Analysis of Incorrect Options** * **Option A:** This describes the process of **alopecia** (specifically androgenetic alopecia). While PCOS patients can experience thinning of scalp hair, the classic effect on body hair follicles in hirsutism is the opposite. * **Options C & D:** These are incorrect because the conversion of a vellus follicle to a terminal follicle is generally **irreversible**. While medical treatment (like OCPs or Spironolactone) can slow the growth and thin the diameter of new hair, it cannot revert a terminal follicle back into a vellus one. This is why physical modalities like laser or electrolysis are required to remove existing terminal hair. ### **NEET-PG High-Yield Pearls** * **Ferriman-Gallwey Score:** The clinical tool used to quantify hirsutism. A score of **≥8** is typically considered significant in the Indian population. * **Site Specificity:** Androgens increase hair growth on the body (hirsutism) but can cause hair loss on the scalp (androgenetic alopecia). * **Key Enzyme:** 5α-reductase is the target for drugs like Finasteride, though it is not first-line in PCOS. * **First-line Medical Management:** Combined Oral Contraceptive Pills (OCPs) are the primary treatment to suppress ovarian androgen production.

Q: A woman presents with amenorrhea, headache, blurred vision, and galactorrhea. What is the most appropriate investigation?

Prolactin levels. ### Explanation The clinical presentation of **amenorrhea** and **galactorrhea** (the "Amenorrhea-Galactorrhea Syndrome") is the classic hallmark of **Hyperprolactinemia**. **Why Prolactin levels is the correct answer:** Prolactin inhibits the pulsatile release of GnRH from the hypothalamus, leading to low LH/FSH and subsequent amenorrhea. Simultaneously, it stimulates milk production (galactorrhea). The presence of **headache and blurred vision** (specifically bitemporal hemianopia) suggests a **Pituitary Adenoma** (Prolactinoma). As the tumor grows, it causes "mass effect" by compressing the optic chiasm and increasing intracranial pressure. Measuring serum prolactin is the essential first step to confirm the diagnosis before proceeding to imaging like an MRI. **Why the other options are incorrect:** * **LH and FSH:** While these levels are often low in hyperprolactinemia (hypogonadotropic hypogonadism), they are non-specific and do not identify the underlying cause of the galactorrhea or visual symptoms. * **HCG:** While pregnancy is the most common cause of secondary amenorrhea and must always be ruled out, it does not typically present with galactorrhea, headaches, and visual field defects. **High-Yield Clinical Pearls for NEET-PG:** * **Hook Effect:** In cases of giant prolactinomas with extremely high prolactin, lab tests may show falsely low levels. Serial dilution is required for an accurate reading. * **Drug-induced:** Always rule out dopamine antagonists (e.g., Metoclopramide, Risperidone) as they are common causes of hyperprolactinemia. * **Treatment:** Medical management with **Dopamine agonists (Cabergoline > Bromocriptine)** is the first-line treatment, even for large macroprolactinomas. Surgery is reserved for refractory cases.

Reproductive Endocrinology Indian Medical PG Practice Questions and MCQs

Question 1: Testicular feminization syndrome is characterized by all of the following except?

A. Absent uterus
B. Primary amenorrhea
C. Normal breast development
D. Presence of Barr body (Correct Answer)

Explanation: **Explanation:** **Testicular Feminization Syndrome (now known as Complete Androgen Insensitivity Syndrome - CAIS)** is a condition where a genetic male (46, XY) has a total resistance to androgens due to a defect in the androgen receptor. **Why Option D is the Correct Answer:** The **Barr body** represents an inactivated X chromosome, typically found in individuals with more than one X chromosome (e.g., 46, XX females or 47, XXY males). Since CAIS patients have a **46, XY genotype**, they possess only one X chromosome, which remains active. Therefore, they are **Barr body negative**. **Analysis of Other Options:** * **A. Absent uterus:** In these patients, the testes are present (usually intra-abdominal) and secrete **Anti-Müllerian Hormone (AMH)**. AMH causes the regression of Müllerian structures, leading to the absence of the uterus, fallopian tubes, and upper third of the vagina. * **B. Primary amenorrhea:** Due to the absence of a uterus and ovaries, these patients typically present during puberty with a failure to start menstruation. * **C. Normal breast development:** Peripheral conversion of testosterone to estrogen (aromatization) occurs. Since there is no androgen action to oppose this estrogen, patients develop normal, often feminine, breast contours (though the nipples/areolae may be pale). **High-Yield Clinical Pearls for NEET-PG:** * **Karyotype:** 46, XY (Genetically male, Phenotypically female). * **Gonads:** Testes (Risk of gonadoblastoma; gonadectomy is recommended after puberty/attainment of height). * **Hair:** Characteristically **absent or scanty** axillary and pubic hair (due to androgen resistance). * **Vagina:** Blind-ending pouch (short vagina). * **Differential Diagnosis:** **Müllerian Agenesis (MRKH Syndrome)**. Distinguishing factor: MRKH has a 46, XX karyotype, normal pubic hair, and normal ovaries.

Question 2: A female presents with normal breast development but scanty pubic hair. What is the most likely diagnosis?

A. Turner's syndrome
B. Testicular feminizing syndrome (Correct Answer)
C. Mullerian agenesis
D. Gonadal dysgenesis

Explanation: **Explanation:** The clinical presentation of **normal breast development** paired with **scanty or absent pubic/axillary hair** is a classic hallmark of **Androgen Insensitivity Syndrome (AIS)**, historically known as **Testicular Feminizing Syndrome**. **1. Why the Correct Answer is Right:** In AIS, the individual has a **46, XY** karyotype and functioning testes that produce testosterone. However, due to a defect in androgen receptors, the body cannot respond to testosterone. * **Breast Development:** Occurs because the high levels of testosterone are peripherally converted to estrogen (aromatization). * **Scanty Pubic Hair:** Pubic and axillary hair growth is dependent on androgens. Since the receptors are non-functional, hair growth is minimal or absent. * **Anatomy:** MIF (Müllerian Inhibiting Factor) is produced, so there is no uterus or fallopian tubes (blind-ending vagina). **2. Why Incorrect Options are Wrong:** * **Turner’s Syndrome (45, XO):** Characterized by "streak gonads" and low estrogen. Patients typically present with **primary amenorrhea and absent breast development** (sexual infantilism). * **Müllerian Agenesis (MRKH Syndrome):** These patients are **46, XX** with normal ovaries. They have **normal breast development AND normal pubic hair** (since androgen receptors are functional), but lack a uterus and upper vagina. * **Gonadal Dysgenesis:** Similar to Turner’s, the lack of functional gonads leads to estrogen deficiency, resulting in a lack of secondary sexual characteristics (no breast development). **High-Yield Clinical Pearls for NEET-PG:** * **Karyotype:** AIS is 46, XY; MRKH is 46, XX. * **Gonads:** In AIS, testes are often found in the inguinal canal or abdomen (risk of gonadoblastoma; requires removal after puberty). * **Differential Diagnosis:** The presence or absence of pubic hair is the most important clinical differentiator between AIS (absent) and MRKH (present).

Question 3: Which of the following tests can differentiate Mullerian agenesis (MRKH syndrome) from complete androgen insensitivity syndrome (testicular feminization syndrome)?

A. 3D Ultrasound
B. MRI
C. Karyotyping (Correct Answer)
D. Serum testosterone levels

Explanation: **Explanation:** Both **Mullerian Agenesis (MRKH Syndrome)** and **Complete Androgen Insensitivity Syndrome (CAIS)** present with primary amenorrhea, a blind vaginal pouch, and well-developed breasts. However, their underlying genetic and hormonal profiles are fundamentally different. **Why Karyotyping is the Correct Answer:** Karyotyping is the definitive diagnostic tool to differentiate these two conditions. * **MRKH Syndrome:** Patients are genetically female (**46, XX**). They have normal ovaries and female-range testosterone levels. * **CAIS:** Patients are genetically male (**46, XY**). They have undescended testes and male-range testosterone levels, but appear phenotypically female because their tissues are unresponsive to androgens. **Analysis of Incorrect Options:** * **A & B (3D Ultrasound/MRI):** While both imaging modalities are excellent for identifying the absence of a uterus and cervix, they cannot reliably distinguish between a 46,XX individual (MRKH) and a 46,XY individual (CAIS) based solely on pelvic anatomy, as both lack Mullerian structures. * **D (Serum Testosterone):** While testosterone levels are significantly higher in CAIS (male range) than in MRKH (female range), **Karyotyping** remains the gold standard for definitive diagnosis and is the preferred initial step in the workup of primary amenorrhea with absent internal organs. **High-Yield Clinical Pearls for NEET-PG:** 1. **Pubic/Axillary Hair:** This is the most important clinical differentiator. It is **normal** in MRKH but **absent or scanty** in CAIS (due to androgen resistance). 2. **Gonads:** In MRKH, ovaries are present (normal ovulation/hormones). In CAIS, testes are present (usually intra-abdominal or inguinal). 3. **Management:** In CAIS, the gonads must be removed (gonadectomy) after puberty to prevent malignancy (gonadoblastoma/dysgerminoma). In MRKH, the focus is on vaginal creation (dilatation or vaginoplasty).

Question 4: A 20-year-old young woman presents with a history of rapidly developing hirsutism and amenorrhea with a change in voice. Which of the following blood tests would be most appropriate to establish a diagnosis?

A. 17-hydroxyprogesterone
B. Dehydroepiandrosterone (DHEA)
C. Testosterone (Correct Answer)
D. Luteinizing hormone (LH) + Follicle-stimulating hormone (FSH) estimation

Explanation: **Explanation:** The clinical presentation of **rapidly developing hirsutism**, **amenorrhea**, and **virilization** (deepening of voice) in a young woman is highly suggestive of an **androgen-secreting tumor** (ovarian or adrenal). 1. **Why Testosterone is the correct answer:** In cases of rapid-onset virilization, the primary goal is to rule out a testosterone-secreting ovarian tumor (e.g., Sertoli-Leydig cell tumor). Serum **Total Testosterone** levels >200 ng/dL are a strong biochemical marker for such neoplasms. While PCOS causes gradual hirsutism, a sudden onset with virilization points toward malignancy or a functional tumor, making testosterone the most critical initial diagnostic test. 2. **Why other options are incorrect:** * **17-hydroxyprogesterone:** This is the screening test for **Congenital Adrenal Hyperplasia (CAH)**. While CAH causes hirsutism, it is usually present from childhood/puberty and rarely presents with such a rapid, fulminant course in a 20-year-old. * **DHEA/DHEA-S:** DHEA-S is a marker for **adrenal** sources of androgens. While it should be measured if an adrenal tumor is suspected (levels >700 µg/dL), Testosterone is generally the more sensitive first-line marker for overall virilization. * **LH/FSH ratio:** This is used to support a diagnosis of **PCOS** (where the ratio is often >2:1). However, PCOS causes slow, progressive hirsutism and does not typically cause voice changes (virilization). **Clinical Pearls for NEET-PG:** * **Rapid onset + Virilization** = Think Androgen-secreting Tumor. * **Gradual onset + Obesity + Irregular periods** = Think PCOS. * **Testosterone >200 ng/dL:** Evaluate for Ovarian Tumor (e.g., Sertoli-Leydig). * **DHEA-S >700 µg/dL:** Evaluate for Adrenal Tumor. * **Deepening of voice and clitoromegaly** are signs of virilization, not just hirsutism, and always require urgent investigation to rule out malignancy.

Question 5: A young female presented with primary amenorrhea. Examination reveals normal breast development and absent axillary hairs. Pelvic examination shows a normally developed vagina with clitoromegaly. On ultrasound, gonads are visible in the inguinal region. What is the most likely diagnosis?

A. Complete androgen insensitivity syndrome
B. Partial androgen insensitivity syndrome (Correct Answer)
C. Mayer Rokitansky Kuster Hauser syndrome
D. Gonadal dysgenesis

Explanation: **Explanation:** The clinical presentation hinges on the spectrum of **Androgen Insensitivity Syndrome (AIS)**, an X-linked recessive condition where a 46,XY individual has a functional defect in androgen receptors. **Why Partial AIS (PAIS) is correct:** In PAIS, there is partial responsiveness to androgens. The presence of **clitoromegaly** (ambiguous genitalia) and **axillary hair** (though often sparse, its presence or the virilization of genitalia distinguishes it from the "Complete" form) are hallmark signs. The patient has normal breast development due to the peripheral conversion of testosterone to estrogen. The presence of **inguinal gonads** (testes) and a short/blind-ending vagina (due to Anti-Müllerian Hormone production by testes) confirms the diagnosis. **Why other options are incorrect:** * **Complete AIS (CAIS):** Presents with a purely female phenotype. There is **no clitoromegaly** and characteristically **absent or very scanty** axillary/pubic hair. * **MRKH Syndrome:** These are 46,XX individuals with normal ovaries. They would have **normal axillary/pubic hair** (normal adrenarche) and no clitoromegaly or inguinal testes. * **Gonadal Dysgenesis (e.g., Turner Syndrome):** Typically presents with **absent breast development** (due to ovarian failure/streak gonads) and elevated gonadotropins. **High-Yield Clinical Pearls for NEET-PG:** * **Karyotype:** Both CAIS and PAIS are **46,XY**. * **The "Hair" Rule:** CAIS = Hairless (absent axillary/pubic hair); MRKH = Hairy (normal hair). * **Management:** In AIS, gonads are removed after puberty (to allow natural height gain and breast development) to prevent **gonadoblastoma/dysgerminoma**, followed by estrogen replacement. * **Differential:** If a patient has primary amenorrhea, absent uterus, but **normal male-range testosterone**, think AIS. If testosterone is in the **female range**, think MRKH.

Question 6: Anti-Müllerian Hormone is:

A. A glycolipid secreted by granulosa cells of the secondary follicle.
B. An indicator that indirectly reflects the primordial follicle pool. (Correct Answer)
C. A hormone that increases progressively across the menopausal transition.
D. A hormone secreted by Müllerian duct derivatives.

Explanation: ### Explanation **Correct Answer: B. An indicator that indirectly reflects the primordial follicle pool.** **Why it is correct:** Anti-Müllerian Hormone (AMH) is a member of the TGF-β superfamily. It is secreted by the **granulosa cells** of pre-antral and small antral follicles (up to 8mm). Since the number of these growing follicles is proportional to the total number of dormant primordial follicles remaining in the ovary, AMH serves as a highly reliable **indirect biochemical marker of the ovarian reserve.** **Analysis of Incorrect Options:** * **Option A:** AMH is a **glycoprotein**, not a glycolipid. While it is secreted by granulosa cells, its production begins in primary follicles and is highest in pre-antral and small antral stages. * **Option C:** AMH levels **decrease** as a woman ages and become undetectable or nearly zero during the menopausal transition, reflecting the exhaustion of the oocyte pool. * **Option D:** In females, AMH is secreted by the ovaries (granulosa cells). In males, it is secreted by the **Sertoli cells** of the testes to cause regression of the Müllerian ducts during fetal development. It is not secreted by the Müllerian ducts themselves. **High-Yield Clinical Pearls for NEET-PG:** * **Cycle Independence:** Unlike FSH, AMH levels remain relatively constant throughout the menstrual cycle, allowing it to be tested on any day. * **PCOS:** AMH levels are characteristically **elevated** in Polycystic Ovary Syndrome due to the high number of small antral follicles. * **Best Marker:** AMH is considered the most sensitive marker for ovarian reserve and is used to predict response to controlled ovarian stimulation in IVF. * **Early Marker:** It is the first marker to show a decline in the aging ovary, preceding changes in FSH or Inhibin B.

Question 7: Which of the following is the best diagnostic method for confirming ovulation?

A. Ultrasound
B. Laparoscopy
C. Endometrial biopsy (Correct Answer)
D. Chromotubation

Explanation: **Explanation:** The correct answer is **Endometrial biopsy**. While several methods can suggest ovulation, an endometrial biopsy is traditionally considered the "gold standard" for confirming that ovulation has occurred and that the corpus luteum is producing adequate progesterone. **1. Why Endometrial Biopsy is Correct:** Ovulation is followed by the formation of the corpus luteum, which secretes **progesterone**. Progesterone induces specific **secretory changes** in the endometrium. Performing a biopsy during the mid-luteal phase (typically day 21-23 of a 28-day cycle) and finding secretory endometrium provides definitive histological proof that the ovary has been exposed to progesterone, thus confirming prior ovulation. **2. Why Other Options are Incorrect:** * **A. Ultrasound:** Serial transvaginal sonography (Folliculometry) is excellent for monitoring follicular growth and disappearance (suggesting rupture), but it is an indirect visualization and cannot confirm the functional hormonal status as accurately as histology. * **B. Laparoscopy:** While it can visualize a *corpus hemorrhagicum* or a stigma on the ovary, it is an invasive surgical procedure and not a routine diagnostic tool for confirming ovulation. * **D. Chromotubation:** This is a procedure performed during laparoscopy to check for **tubal patency** using methylene blue dye; it has no role in assessing ovulation. **NEET-PG High-Yield Pearls:** * **Most accurate single-day test:** Serum Progesterone levels >3 ng/ml (measured on Day 21) are the most common clinical method to confirm ovulation. * **Luteal Phase Defect (LPD):** Diagnosed if the endometrial dating lags by more than 2 days behind the actual menstrual day. * **Spinnbarkeit Effect:** Refers to the elasticity of cervical mucus under estrogen influence (pre-ovulatory); this disappears after ovulation due to progesterone.

Question 8: What is the effect of elevated androgens on hair follicles in Polycystic Ovary Syndrome (PCOS)?

A. Conversion of terminal hair to vellus hair.
B. Conversion of vellus hair to terminal hair. (Correct Answer)
C. Reversible conversion of vellus hair to terminal hair.
D. Reversible conversion of terminal hair to vellus hair.

Explanation: In Polycystic Ovary Syndrome (PCOS), hyperandrogenism is a hallmark feature. The effect of androgens on hair follicles is site-specific and mediated primarily by the conversion of Testosterone to **Dihydrotestosterone (DHT)** via the enzyme **5α-reductase** within the hair follicle. ### **Explanation of the Correct Answer (B)** In androgen-sensitive areas (face, chest, lower abdomen), elevated levels of androgens act on **vellus hairs**—which are fine, short, and non-pigmented—and stimulate their transformation into **terminal hairs**, which are coarse, long, and darkly pigmented. This process is known as **hirsutism**. ### **Analysis of Incorrect Options** * **Option A:** This describes the process of **alopecia** (specifically androgenetic alopecia). While PCOS patients can experience thinning of scalp hair, the classic effect on body hair follicles in hirsutism is the opposite. * **Options C & D:** These are incorrect because the conversion of a vellus follicle to a terminal follicle is generally **irreversible**. While medical treatment (like OCPs or Spironolactone) can slow the growth and thin the diameter of new hair, it cannot revert a terminal follicle back into a vellus one. This is why physical modalities like laser or electrolysis are required to remove existing terminal hair. ### **NEET-PG High-Yield Pearls** * **Ferriman-Gallwey Score:** The clinical tool used to quantify hirsutism. A score of **≥8** is typically considered significant in the Indian population. * **Site Specificity:** Androgens increase hair growth on the body (hirsutism) but can cause hair loss on the scalp (androgenetic alopecia). * **Key Enzyme:** 5α-reductase is the target for drugs like Finasteride, though it is not first-line in PCOS. * **First-line Medical Management:** Combined Oral Contraceptive Pills (OCPs) are the primary treatment to suppress ovarian androgen production.

Question 9: A woman presents with amenorrhea. She has negative bleeding after a progesterone challenge test but bleeds following a combined estrogen-progesterone challenge test. What is the most likely underlying cause?

A. Anovulation
B. Asherman syndrome
C. Pregnancy
D. Pituitary tumor (Correct Answer)

Explanation: This question tests the systematic approach to secondary amenorrhea using hormonal challenge tests. ### **Mechanism and Logic** 1. **Progesterone Challenge Test (PCT):** A negative result (no bleeding) indicates either **inadequate endogenous estrogen** (failed to prime the endometrium) or an **outflow tract obstruction**. 2. **Estrogen-Progesterone Challenge Test (EPCT):** Bleeding after this test confirms that the **outflow tract and endometrium are functional**. Since the patient bled after EPCT but not after PCT, the defect lies in the **Hypothalamic-Pituitary-Ovarian (HPO) axis**. The lack of endogenous estrogen prevents endometrial proliferation. A **Pituitary tumor** (like a prolactinoma) suppresses GnRH pulsatility, leading to low FSH/LH and subsequent hypoestrogenism, making it the most likely cause among the options. ### **Analysis of Incorrect Options** * **A. Anovulation:** In anovulation (e.g., PCOS), there is "unopposed estrogen." The endometrium is primed, so the patient would **bleed** after a Progesterone Challenge. * **B. Asherman Syndrome:** This involves intrauterine synechiae (outflow tract obstruction). The patient would **not bleed** even after the EPCT because the endometrial cavity is obliterated. * **C. Pregnancy:** This is the most common cause of secondary amenorrhea. However, high endogenous progesterone levels during pregnancy prevent withdrawal bleeding in both tests. ### **High-Yield NEET-PG Pearls** * **Step 1 in Amenorrhea:** Always rule out pregnancy (uHCG). * **Step 2:** Progesterone Challenge (Medroxyprogesterone acetate 10mg for 5–10 days). * **Bleeding after PCT:** Diagnosis is **Anovulation** (HPO axis is intact, but no ovulation). * **No bleeding after EPCT:** Diagnosis is **Outflow tract obstruction** (Asherman syndrome or Mullerian anomalies). * **Bleeding after EPCT:** Diagnosis is **HPO Axis Failure** (Hypogonadotropic hypogonadism or Premature Ovarian Failure). Check FSH levels next to differentiate.

Question 10: A woman presents with amenorrhea, headache, blurred vision, and galactorrhea. What is the most appropriate investigation?

A. Prolactin levels (Correct Answer)
B. Luteinizing hormone (LH)
C. Follicle-stimulating hormone (FSH)
D. Human chorionic gonadotropin (HCG)

Explanation: ### Explanation The clinical presentation of **amenorrhea** and **galactorrhea** (the "Amenorrhea-Galactorrhea Syndrome") is the classic hallmark of **Hyperprolactinemia**. **Why Prolactin levels is the correct answer:** Prolactin inhibits the pulsatile release of GnRH from the hypothalamus, leading to low LH/FSH and subsequent amenorrhea. Simultaneously, it stimulates milk production (galactorrhea). The presence of **headache and blurred vision** (specifically bitemporal hemianopia) suggests a **Pituitary Adenoma** (Prolactinoma). As the tumor grows, it causes "mass effect" by compressing the optic chiasm and increasing intracranial pressure. Measuring serum prolactin is the essential first step to confirm the diagnosis before proceeding to imaging like an MRI. **Why the other options are incorrect:** * **LH and FSH:** While these levels are often low in hyperprolactinemia (hypogonadotropic hypogonadism), they are non-specific and do not identify the underlying cause of the galactorrhea or visual symptoms. * **HCG:** While pregnancy is the most common cause of secondary amenorrhea and must always be ruled out, it does not typically present with galactorrhea, headaches, and visual field defects. **High-Yield Clinical Pearls for NEET-PG:** * **Hook Effect:** In cases of giant prolactinomas with extremely high prolactin, lab tests may show falsely low levels. Serial dilution is required for an accurate reading. * **Drug-induced:** Always rule out dopamine antagonists (e.g., Metoclopramide, Risperidone) as they are common causes of hyperprolactinemia. * **Treatment:** Medical management with **Dopamine agonists (Cabergoline > Bromocriptine)** is the first-line treatment, even for large macroprolactinomas. Surgery is reserved for refractory cases.

Practice by Chapter

Hypothalamic-Pituitary-Ovarian Axis

Practice Questions

Disorders of Puberty

Practice Questions

Hirsutism and Virilization

Practice Questions

Primary Ovarian Insufficiency

Practice Questions

Hyperprolactinemia

Practice Questions

Hyperandrogenism

Practice Questions

Metabolic Dysfunction in PCOS

Practice Questions

Neuroendocrine Disorders and Reproduction

Practice Questions

Hormonal Evaluation and Testing

Practice Questions

Ovulation Induction

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free